

### Complete Listing of the Claims

1. (previously presented) Crystalline *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride.
2. (previously presented) The compound of Claim 1 which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at  $2\theta$  values selected from the group consisting of  $15.61\pm 0.2$ ,  $16.32\pm 0.2$ ,  $19.50\pm 0.2$ ,  $24.25\pm 0.2$ ,  $24.92\pm 0.2$ ,  $25.45\pm 0.2$ ,  $28.67\pm 0.2$ , and  $31.16\pm 0.2$ .
3. (previously presented) The compound of Claim 1 wherein the x-ray powder diffraction pattern comprises diffraction peaks at  $2\theta$  values of  $24.25\pm 0.2$ ,  $24.92\pm 0.2$ , and  $25.45\pm 0.2$ .
4. (previously presented) The compound of Claim 1 which is characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1.
5. (previously presented) The compound of Claim 1 having an infrared absorption spectrum with significant absorption bands at  $696\pm 1$ ,  $752\pm 1$ ,  $787\pm 1$ ,  $827\pm 1$ ,  $873\pm 1$ ,  $970\pm 1$ ,  $986\pm 1$ ,  $1020\pm 1$ ,  $1055\pm 1$ ,  $1066\pm 1$ ,  $1101\pm 1$ ,  $1197\pm 1$ ,  $1293\pm 1$ ,  $1371\pm 1$ ,  $1440\pm 1$ ,  $1542\pm 1$ ,  $1597\pm 1$ ,  $1658\pm 1$ ,  $2952\pm 1$ ,  $3372\pm 1$ , and  $3555\pm 1$   $\text{cm}^{-1}$ .
6. (previously presented) The compound of Claim 1 which is characterized by a differential scanning calorimetry trace which shows an onset of endothermic heat flow at about  $200^{\circ}\text{C}$ .
7. (previously presented) A hydrochloride salt of *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine having an x-ray powder diffraction pattern having two or

more diffraction peaks at  $2\theta$  values selected from the group consisting of  $15.61\pm0.2$ ,  $16.32\pm0.2$ ,  $19.50\pm0.2$ ,  $24.25\pm0.2$ ,  $24.92\pm0.2$ ,  $25.45\pm0.2$ ,  $28.67\pm0.2$ , and  $31.16\pm0.2$ .

8. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a pharmaceutically acceptable carrier.

9. (previously presented) The pharmaceutical composition of Claim 8, wherein the composition comprises particles of crystalline *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride having a size ranging from about 1  $\mu\text{m}$  to about 10  $\mu\text{m}$ .

10. (previously presented) The pharmaceutical composition of Claim 8, wherein the composition further comprises a therapeutically effective amount of one or more other therapeutic agents.

11. (previously presented) The pharmaceutical composition of Claim 8, wherein the composition is formulated for administration by inhalation.

12. (previously presented) A combination comprising the compound of Claim 1 and one or more other therapeutic agents.

13. (previously presented) The combination of Claim 12 wherein the other therapeutic agent is a corticosteroid, an anticholinergic agent, or a PDE4 inhibitor.

14. (previously presented) A combination comprising a compound of Claim 1 and  $6\alpha,9\alpha$ -difluoro- $17\alpha$ -[(2-furanylcarbonyl)oxy]- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-fluoromethyl ester or  $6\alpha,9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo- $17\alpha$ -propionyloxy- androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-(2-oxo-tetrahydro-furan-3S-yl) ester.

15. (previously presented) A process for preparing crystalline *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride, the process comprising the steps of:

- (a) dissolving *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine in a first polar solvent to form a first solution; and
- (b) adding hydrochloric acid to form a second solution from which a crystalline product is formed.

16. (previously presented) The process of Claim 15 wherein the second solution comprises isopropanol and water in a ratio of isopropanol:water of from about 4:1 to about 10:1, volume to volume.

17. (previously presented) The process of Claim 15 further comprising:
- (a) dissolving the product of Claim 15 in a second polar solvent; and
  - (b) adding between about 0.5 and about 1.5 equivalents of hydrochloric acid per mole of free base and a third polar solvent to form a third solution from which a crystalline product is formed.

18. (previously presented) The crystalline hydrochloride salt produced by the process of Claim 15.

19. (previously presented) The crystalline hydrochloride salt of Claim 18 wherein the salt has an x-ray powder diffraction pattern having two or more diffraction peaks at  $2\theta$  values selected from the group consisting of  $15.61\pm 0.2$ ,  $16.32\pm 0.2$ ,  $19.50\pm 0.2$ ,  $24.25\pm 0.2$ ,  $24.92\pm 0.2$ ,  $25.45\pm 0.2$ ,  $28.67\pm 0.2$ , and  $31.16\pm 0.2$ .

20. (previously presented) A pharmaceutical composition comprising:
- (a) *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride;
  - (b) a buffering agent; and
  - (c) water;

wherein the buffering agent is present in an amount sufficient to provide the composition with a pH in the range of between about 4 and about 6.

21. (previously presented) The pharmaceutical composition of Claim 20 wherein the buffering agent is present in an amount sufficient to provide the composition with a pH in the range of between about 5 and about 5.5.

22. (previously presented) The pharmaceutical composition of Claim 20 where the buffering agent comprises a citrate species.

23. (previously presented) The pharmaceutical composition of Claim 20 wherein the composition is isotonic.

24. (previously presented) The pharmaceutical composition of Claim 23 wherein the composition further comprises a sufficient amount of sodium chloride to render the composition isotonic.

25. (previously presented) The pharmaceutical composition of Claim 20, wherein the composition further comprises a surfactant.

26. (previously presented) The pharmaceutical composition of Claim 20, wherein the composition further comprises a therapeutically effective amount of one or more other therapeutic agents.

27. (previously presented) A kit comprising:  
(a) a nebulizer device; and  
(b) a container whose contents comprise the pharmaceutical composition of Claim 20.

28. (previously presented) A process for preparing a pharmaceutical composition for use in a nebulizer, the process comprising the steps of:

- (a) dissolving crystalline *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride in an acidic aqueous solution comprising a buffering agent; and
- (b) adding a base until the composition has a pH of between about 4 and about 6.

29. (previously presented) The process of Claim 28 wherein the acidic aqueous solution is an isotonic solution.

30. (previously presented) The process of Claim 28 wherein step (b) comprises adding NaOH until the composition has a pH in the range of between about 5 and about 5.5.

31. (previously presented) A method of treating a disease or condition in a mammal associated with  $\beta_2$  adrenergic receptor activity, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of Claim 8 or Claim 20.

32. (previously presented) The method of Claim 31 wherein the disease or condition is a pulmonary disease.

33. (previously presented) The method of Claim 32 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.


34. (previously presented) The method of Claim 31 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.

35. (previously presented) The method of Claim 31 wherein the method further comprises administering a therapeutically effective amount of one or more other therapeutic agents.

36. (previously presented) The method of Claim 31 wherein the other therapeutic agent is a corticosteroid, an anticholinergic agent, or a PDE4 inhibitor.

37. (previously presented) The method of Claim 35 wherein the other therapeutic agent is 6 $\alpha$ ,9 $\alpha$ -difluoro-17 $\alpha$ -[(2-furanylcarbonyl)oxy]-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester or 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -propionyloxy- androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-(2-oxo-tetrahydro-furan-3S-yl) ester.

38. (previously presented) A process for preparing 2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethylamine (2):



2

the process comprising the steps of:

- (a) reacting 2-(4-aminophenyl)ethylamine or a salt thereof with a sufficient amount of base to substantially deprotonate the 4-amino group; and
- (b) reacting the product of step (a) with (*R*)-styrene oxide to provide compound 2.

39. (previously presented) The process of Claim 38, wherein steps (a) and (b) are conducted in a solvent system comprising a polar aprotic solvent.

40. (previously presented) The process of Claim 38, wherein the process further comprises forming a crystalline salt of compound 2.